← All trials
NCT06319820
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2024
- Primary completion
- Jun 28, 2028
- Completion date
- Jun 28, 2028
- First posted
- Mar 20, 2024
- Last posted
- Oct 26, 2024
- Enrollment
- 540
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johnson and JohnsonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.